BioCentury
ARTICLE | Clinical News

QR-333: Phase IIb start

October 2, 2006 7:00 AM UTC

By year end, QGLY will start a 12-week, double-blind, placebo-controlled Phase IIb trial of thrice-daily QR-333 in up to 200 patients with diabetic neuropathy. ...